Sanvar Salvation May Lie In Reanalyzing Data From Flawed Trial, Panel Says

Debiovision's next step for its acute esophageal bleeding drug Sanvar (vapreotide) should be to go back and reanalyze the existing data from its pivotal trial before attempting additional trials to show efficacy for the treatment